Alvotech_logo.jpg
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET | Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
Alvotech_logo.jpg
Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahliðstæðuna í háum styrk með útskiptanleika við Humira
April 19, 2024 06:10 ET | Alvotech
Langtímasamningur hefur náðst við leiðandi innkaupaaðila lyfja í Bandaríkjunum um sölu- og dreifingu á líftæknilyfjahliðstæðu Alvotech í háum styrk með útskiptanleika við HumiraMeð þessum samningi...
Alvotech_logo.jpg
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET | Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
Alvotech hlýtur mark
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara
April 16, 2024 17:30 ET | Alvotech
Markaðsleyfið er fyrir notkun lyfsins til meðferðar bæði á fullorðnum og börnum Þetta er önnur líftæknilyfjahliðstæða Alvotech sem hlýtur markaðsleyfi í Bandaríkjunum Gert er ráð fyrir að Selarsdi...
Alvotech and Teva An
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024 17:30 ET | Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
Alvotech and Teva An
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024 17:30 ET | Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
Alvotech_logo.jpg
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
April 03, 2024 07:41 ET | Alvotech
REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech streymir ky
Alvotech streymir kynningu fyrir fjárfesta 3. apríl 2024 kl. 12:15 að íslenskum tíma
April 03, 2024 06:43 ET | Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið myndi streyma stuttri kynningu fyrir fjárfesta kl. 12:15 að íslenskum tíma í dag, 3. apríl 2024. Anil Okay, framkvæmdastjóri viðskipta mun þar...
Alvotech Hosts Audio
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
April 03, 2024 06:43 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a...
Alvotech_logo.jpg
Alvotech Announces Increase in Number of Own Shares
March 22, 2024 16:15 ET | Alvotech
REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...